scholarly journals Achievement of constitutive fluorescent pLEXSY-egfp Leishmania braziliensis and its application as an alternative method for drug screening in vitro

2017 ◽  
Vol 112 (2) ◽  
pp. 155-159 ◽  
Author(s):  
Matheus Silva e Bastos ◽  
◽  
Luciana Ângelo de Souza ◽  
Thiago Souza Onofre ◽  
Abelardo Silva Júnior ◽  
...  
Keyword(s):  
Drug Screening ◽  
Leishmania Braziliensis ◽  
Alternative Method ◽  
Screening In Vitro

Substrate stiffness influences the outcome of antitumor drug screening in vitro

2013 ◽  
Vol 55 (1) ◽  
pp. 121-131 ◽  
Author(s):  
Jiantao Feng ◽  
Yong Tang ◽  
Yonggang Xu ◽  
Quanmei Sun ◽  
Fulong Liao ◽  
...  
Keyword(s):  
Drug Screening ◽  
Antitumor Drug ◽  
Substrate Stiffness ◽  
Screening In Vitro

scholarly journals Mass-producible microporous silicon membranes for specific leukocyte subset isolation, immunophenotyping, and personalized immunomodulatory drug screening in vitro

Lab on a Chip ◽  
2019 ◽  
Vol 19 (18) ◽  
pp. 3065-3076 ◽  
Author(s):  
Andrew Stephens ◽  
Robert Nidetz ◽  
Nicolas Mesyngier ◽  
Meng Ting Chung ◽  
Yujing Song ◽  
...  
Keyword(s):  
Microfluidic Device ◽  
Drug Screening ◽  
Leukocyte Subset ◽  
Immunomodulatory Drug ◽  
Silicon Membranes ◽  
On Chip ◽  
Leukocyte Populations ◽  
Screening In Vitro

Si micromachining processes were used to create a mass-producible immunophenotyping microfluidic device which can isolate and stimulate specific leukocyte populations, enabling measurement of secreted cytokines on-chip via a no-wash immunoassay.

Toxoplasma gondii: A simple high-throughput assay for drug screening in vitro

2009 ◽  
Vol 121 (2) ◽  
pp. 132-136 ◽  
Author(s):  
ChunMei Jin ◽  
Kusuma Kaewintajuk ◽  
JingHua Jiang ◽  
WooJin Jeong ◽  
Masaki Kamata ◽  
...  
Keyword(s):  
Toxoplasma Gondii ◽  
High Throughput ◽  
Drug Screening ◽  
High Throughput Assay ◽  
Screening In Vitro

scholarly journals Acanthamoeba castellanii : A new high-throughput method for drug screening in vitro

Acta Tropica ◽  
2016 ◽  
Vol 164 ◽  
pp. 95-99 ◽  
Author(s):  
Antonio Ortega-Rivas ◽  
José M. Padrón ◽  
Basilio Valladares ◽  
Hany M. Elsheikha
Keyword(s):  
High Throughput ◽  
Drug Screening ◽  
Acanthamoeba Castellanii ◽  
High Throughput Method ◽  
Screening In Vitro

Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites

2008 ◽  
Vol 38 (14) ◽  
pp. 1651-1662 ◽  
Author(s):  
B. Franke-Fayard ◽  
D. Djokovic ◽  
M.W. Dooren ◽  
J. Ramesar ◽  
A.P. Waters ◽  
...  
Keyword(s):  
Drug Screening ◽  
Plasmodium Berghei ◽  
Antimalarial Drug ◽  
Screening In Vitro

scholarly journals In Vitro Evaluation of the Potential Pharmacological Activity and Molecular Targets of New Benzimidazole-Based Schiff Base Metal Complexes

Antibiotics ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 728
Author(s):  
Alberto Aragón-Muriel ◽  
Yamil Liscano ◽  
Yulieth Upegui ◽  
Sara M. Robledo ◽  
María Teresa Ramírez-Apan ◽  
...  
Keyword(s):  
Schiff Base ◽  
Molecular Docking ◽  
Lanthanide Complexes ◽  
Human Tumor ◽  
Model Membranes ◽  
Leishmania Braziliensis ◽  
Cytotoxic Activities ◽  
Schiff Base Ligands ◽  
Major Interest

Metal-based drugs, including lanthanide complexes, have been extremely effective in clinical treatments against various diseases and have raised major interest in recent decades. Hence, in this work, a series of lanthanum (III) and cerium (III) complexes, including Schiff base ligands derived from (1H-benzimidazol-2-yl)aniline, salicylaldehyde, and 2,4-dihydroxybenzaldehyde were synthesized and characterized using different spectroscopic methods. Besides their cytotoxic activities, they were examined in human U-937 cells, primate kidney non-cancerous COS-7, and six other, different human tumor cell lines: U251, PC-3, K562, HCT-15, MCF-7, and SK-LU-1. In addition, the synthesized compounds were screened for in vitro antiparasitic activity against Leishmania braziliensis, Plasmodium falciparum, and Trypanosoma cruzi. Additionally, antibacterial activities were examined against two Gram-positive strains (S. aureus ATCC® 25923, L. monocytogenes ATCC® 19115) and two Gram-negative strains (E. coli ATCC® 25922, P. aeruginosa ATCC® 27583) using the microdilution method. The lanthanide complexes generally exhibited increased biological activity compared with the free Schiff base ligands. Interactions between the tested compounds and model membranes were examined using differential scanning calorimetry (DSC), and interactions with calf thymus DNA (CT-DNA) were investigated by ultraviolet (UV) absorption. Molecular docking studies were performed using leishmanin (1LML), cruzain (4PI3), P. falciparum alpha-tubulin (GenBank sequence CAA34101 [453 aa]), and S.aureus penicillin-binding protein 2a (PBP2A; 5M18) as the protein receptors. The results lead to the conclusion that the synthesized compounds exhibited a notable effect on model membranes imitating mammalian and bacterial membranes and rolled along DNA strands through groove interactions. Interactions between the compounds and studied receptors depended primarily on ligand structures in the molecular docking study.

scholarly journals The Current Challenges for Drug Discovery in CNS Remyelination

2021 ◽  
Vol 22 (6) ◽  
pp. 2891
Author(s):  
Sonia Balestri ◽  
Alice Del Giovane ◽  
Carola Sposato ◽  
Marta Ferrarelli ◽  
Antonella Ragnini-Wilson
Keyword(s):  
Drug Screening ◽  
Myelin Sheath ◽  
Time Window ◽  
In Vitro Models ◽  
Adult Brain ◽  
Pharmacological Intervention ◽  
Cellular Models ◽  
New Findings ◽  
Myelin Injury

The myelin sheath wraps around axons, allowing saltatory currents to be transmitted along neurons. Several genetic, viral, or environmental factors can damage the central nervous system (CNS) myelin sheath during life. Unless the myelin sheath is repaired, these insults will lead to neurodegeneration. Remyelination occurs spontaneously upon myelin injury in healthy individuals but can fail in several demyelination pathologies or as a consequence of aging. Thus, pharmacological intervention that promotes CNS remyelination could have a major impact on patient’s lives by delaying or even preventing neurodegeneration. Drugs promoting CNS remyelination in animal models have been identified recently, mostly as a result of repurposing phenotypical screening campaigns that used novel oligodendrocyte cellular models. Although none of these have as yet arrived in the clinic, promising candidates are on the way. Many questions remain. Among the most relevant is the question if there is a time window when remyelination drugs should be administrated and why adult remyelination fails in many neurodegenerative pathologies. Moreover, a significant challenge in the field is how to reconstitute the oligodendrocyte/axon interaction environment representative of healthy as well as disease microenvironments in drug screening campaigns, so that drugs can be screened in the most appropriate disease-relevant conditions. Here we will provide an overview of how the field of in vitro models developed over recent years and recent biological findings about how oligodendrocytes mature after reactivation of their staminal niche. These data have posed novel questions and opened new views about how the adult brain is repaired after myelin injury and we will discuss how these new findings might change future drug screening campaigns for CNS regenerative drugs.

Sign in / Sign up

Export Citation Format

Share Document